The field of cancer immunotherapy and checkpoint blockade has focused largely on direct effects on T cells. In this issue of Immunity, Garris et al. (2018) show that the efficacy of anti-PD-1 therapy depends on a T-cell-dendritic-cell (DC) licensing loop fueled by IFN-γ and IL-12, thereby establishing a central role for DCs in promoting anti-cancer T cell immunity during checkpoint blockade.

中文翻译：

---

树突状细胞反击

癌症免疫疗法和检查站封锁领域主要集中在对T细胞的直接作用上。在此期《免疫》中，加里斯（Garris）等人。（2018）显示抗PD-1疗法的功效取决于IFN-γ和IL-12推动的T细胞树突状细胞（DC）许可回路，从而在DC促进抗检查站封锁期间的癌症T细胞免疫力。